Neulasta

Graphic image of a drug capsule opening and percentages falling out
Biotech

Coherus to lose 30% of staff as part of Udenyca sale to Accord

Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma.
James Waldron Mar 11, 2025 7:30am
Job application

Coherus slashes staff by a third after biosimilar knockback

Jun 29, 2017 9:48am
FDA

Coherus' Amgen biosimilar is rejected by FDA; stock plummets

Jun 12, 2017 8:44am
Novartis

After FDA rejection, Novartis pulls Amgen biosim candidate from EMA

Jan 27, 2017 7:23am